Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine

Peter Rauko, Ladislav Novotny, Ima Dovinova, Luba Hunakova, Thomas Szekeres, Hiremagalur N. Jayaram

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.

Original languageEnglish
Pages (from-to)387-394
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Volume12
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Staurosporine
Cisplatin
Leukemia L1210
Leukemia
3-(1-deoxyribofuranosyl)benzamide
DNA Fragmentation
Combination Drug Therapy
Nucleosides
Cell Cycle
Cell Death
Cell Culture Techniques
Apoptosis
DNA
Therapeutics

Keywords

  • Apoptosis
  • Benzamide riboside
  • Cisplatin
  • Cytotoxicity
  • Murine leukemia cells
  • Staurosporine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. / Rauko, Peter; Novotny, Ladislav; Dovinova, Ima; Hunakova, Luba; Szekeres, Thomas; Jayaram, Hiremagalur N.

In: European Journal of Pharmaceutical Sciences, Vol. 12, No. 4, 2001, p. 387-394.

Research output: Contribution to journalArticle

Rauko, Peter ; Novotny, Ladislav ; Dovinova, Ima ; Hunakova, Luba ; Szekeres, Thomas ; Jayaram, Hiremagalur N. / Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. In: European Journal of Pharmaceutical Sciences. 2001 ; Vol. 12, No. 4. pp. 387-394.
@article{168996bff72144cca72f586f00d42e73,
title = "Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine",
abstract = "Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.",
keywords = "Apoptosis, Benzamide riboside, Cisplatin, Cytotoxicity, Murine leukemia cells, Staurosporine",
author = "Peter Rauko and Ladislav Novotny and Ima Dovinova and Luba Hunakova and Thomas Szekeres and Jayaram, {Hiremagalur N.}",
year = "2001",
doi = "10.1016/S0928-0987(00)00180-9",
language = "English",
volume = "12",
pages = "387--394",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine

AU - Rauko, Peter

AU - Novotny, Ladislav

AU - Dovinova, Ima

AU - Hunakova, Luba

AU - Szekeres, Thomas

AU - Jayaram, Hiremagalur N.

PY - 2001

Y1 - 2001

N2 - Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.

AB - Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.

KW - Apoptosis

KW - Benzamide riboside

KW - Cisplatin

KW - Cytotoxicity

KW - Murine leukemia cells

KW - Staurosporine

UR - http://www.scopus.com/inward/record.url?scp=0035108339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035108339&partnerID=8YFLogxK

U2 - 10.1016/S0928-0987(00)00180-9

DO - 10.1016/S0928-0987(00)00180-9

M3 - Article

VL - 12

SP - 387

EP - 394

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

IS - 4

ER -